ATE277947T1 - Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung - Google Patents

Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung

Info

Publication number
ATE277947T1
ATE277947T1 AT98939708T AT98939708T ATE277947T1 AT E277947 T1 ATE277947 T1 AT E277947T1 AT 98939708 T AT98939708 T AT 98939708T AT 98939708 T AT98939708 T AT 98939708T AT E277947 T1 ATE277947 T1 AT E277947T1
Authority
AT
Austria
Prior art keywords
immunogenic
polypetids
altered cell
cell localization
recombinant vector
Prior art date
Application number
AT98939708T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Jean-Marc Balloul
Nadine Bizouarne
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE277947T1 publication Critical patent/ATE277947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98939708T 1997-07-18 1998-07-17 Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung ATE277947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709152A FR2766091A1 (fr) 1997-07-18 1997-07-18 Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
PCT/FR1998/001576 WO1999003885A1 (fr) 1997-07-18 1998-07-17 Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee

Publications (1)

Publication Number Publication Date
ATE277947T1 true ATE277947T1 (de) 2004-10-15

Family

ID=9509372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939708T ATE277947T1 (de) 1997-07-18 1998-07-17 Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung

Country Status (11)

Country Link
US (2) US6884786B1 (de)
EP (1) EP0989999B1 (de)
JP (2) JP4489288B2 (de)
AT (1) ATE277947T1 (de)
AU (1) AU749054B2 (de)
CA (1) CA2296797C (de)
DE (1) DE69826661T2 (de)
ES (1) ES2229528T3 (de)
FR (1) FR2766091A1 (de)
PT (1) PT989999E (de)
WO (1) WO1999003885A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7348014B2 (en) * 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AU2003221650A1 (en) * 2002-04-24 2003-11-10 Universite Libre De Bruxelles Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante
EP2013230A2 (de) * 2006-04-21 2009-01-14 Transgene S.A. Auf hpv-16 basierender papillomavirusimfpstoff
BRPI0710242A2 (pt) * 2006-04-21 2011-08-09 Transgene Sa uso de uma composição
CN101063142B (zh) * 2006-04-30 2012-08-22 中国医学科学院基础医学研究所 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
RU2462513C2 (ru) 2007-05-15 2012-09-27 Трансген С.А. Векторы для множественной генной экспрессии
TW200844230A (en) * 2007-05-15 2008-11-16 Transgene Sa Signaling peptides
US9149517B2 (en) * 2007-11-02 2015-10-06 The Johns Hopkins University Multitype HPV peptide compositions and methods for treatment or prevention of human papillomavirus infection
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
EP2387414A1 (de) 2009-01-13 2011-11-23 Transgene SA Verwendung einer saccharomyces cerevisiae mitochondrialen nukleinsäuren-fraktion zur immunstimulation
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
IN2012DN01577A (de) 2009-07-21 2015-06-05 Transgene Sa
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
WO2011073741A1 (en) 2009-12-18 2011-06-23 Transgene Sa A method and a system for automatically processing multiple measurements of biological quantifiable parameters
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013151733A1 (en) 2012-04-06 2013-10-10 Hyclone Laboratories, Inc. Fluid mixing system with flexible drive line and foldable impeller
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN113975988B (zh) 2015-12-29 2024-09-03 生命科技股份有限公司 具有侧向移位的柔性驱动线的流体混合系统及使用方法
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (de) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stabile virushaltige zusammensetzung
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
CN111699240A (zh) 2018-01-17 2020-09-22 生命技术公司 用于细胞培养缩放的系统和方法
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
US20230405105A1 (en) 2019-09-20 2023-12-21 Transgene Sa Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
FR2583770B1 (fr) 1985-06-21 1988-08-19 Transgene Sa Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR2600079B1 (fr) * 1986-06-16 1989-10-20 Transgene Sa Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
FR2617715B1 (fr) 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
WO1994017187A1 (en) * 1993-01-29 1994-08-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services CLONING AND EXPRESSION OF PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING TARGET ANTIGEN, Pfs230
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
AU724621B2 (en) * 1996-01-29 2000-09-28 Georgetown University Amplification of response from expressed recombinant protein
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6149906A (en) * 1997-09-20 2000-11-21 Osiris Therapeutics, Inc. Antigen presenting cells of the adipocyte lineage

Also Published As

Publication number Publication date
AU749054B2 (en) 2002-06-20
JP2010057500A (ja) 2010-03-18
JP4489288B2 (ja) 2010-06-23
PT989999E (pt) 2005-01-31
US6884786B1 (en) 2005-04-26
US20050159386A1 (en) 2005-07-21
CA2296797A1 (fr) 1999-01-28
ES2229528T3 (es) 2005-04-16
EP0989999B1 (de) 2004-09-29
EP0989999A1 (de) 2000-04-05
WO1999003885A1 (fr) 1999-01-28
JP2001510201A (ja) 2001-07-31
FR2766091A1 (fr) 1999-01-22
DE69826661T2 (de) 2005-10-06
DE69826661D1 (de) 2004-11-04
CA2296797C (fr) 2011-02-08
AU8812798A (en) 1999-02-10
US7332478B2 (en) 2008-02-19

Similar Documents

Publication Publication Date Title
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
FI971783A7 (fi) Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
AR017510A1 (es) Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet
AU1750297A (en) Humanized green fluorescent protein genes and methods
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
DK1222298T3 (da) Vektorer og fremgangsmåder til rekombinant proteinekspression
DE69131882D1 (en) Asiloglycoproteine des hepatitis c-virus
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
NZ518999A (en) Vaccine compositions
YU299A (en) Truncated soluble tumor necrosis factor type-i and type-ii
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
WO2001025438A3 (en) Ifn-alpha homologues
EP1156103A3 (de) Oplophorus Luciferase
ATE331801T1 (de) Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2
WO2000012741A3 (fr) Systeme d'expression inductible
DE69738671D1 (de) Peptidantagonisten von dp transkriptionsfaktoren
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
WO2001098355A3 (en) Cgi-69 compositions and methods of use
NO962023L (no) Endotelin-konverterende enzym
GB2409680A (en) Methods for controlling proliferation of cells
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0989999

Country of ref document: EP